Video

Dr. Benson on Challenges of Active Surveillance for Prostate Cancer

Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses potential issues with active surveillance for patients with intermediate-risk prostate cancer.

Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses potential issues with active surveillance for patients with intermediate-risk prostate cancer.

A Sunnybrook Health Sciences Centre study of patients with low- or intermediate-risk prostate cancer who were managed with an active surveillance, found that intermediate-risk patients had a lower rate of prostate cancer—specific survival and a higher rate of recurrence when compared to those considered low-risk managed with active surveillance.

A single transrectal ultrasonography should not be used to select patients for active surveillance, says Benson. Genomic testing, MRI and more extensive biopsies are needed to give oncologists more reassurance that placing a patient on surveillance is the best course of action.

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center